Details for Patent: 4,562,829

Summary for Patent: 4,562,829

Title:	Strontium-rubidium infusion system
Abstract:	The strontium-rubidium infusion system includes means for generating a solution containing rubidium-82, measuring the radioactivity in the solution, and infusing it into a patient in order to perform various studies on the patient's heart. The system includes a wash syringe which can be used by a physician to manually inject a bolus containing a large amount of radioactivity directly into a patient in order to perform first pass ventriculography studies.
Inventor(s):	Bergner; Brian C. (Lawrenceville, NJ)
Assignee:	E. R. Squibb & Sons, Inc. (Princeton, NJ)
Application Number:	06/605,758
Patent Claim Types: see list of patent claims	Formulation;
Scope and claims summary:	Genentech's Epidermal Growth Factor Patent: A Milestone in Biotechnology United States Patent 4562829, granted in 1986, marks a significant development in the biotechnology sector, particularly in the field of recombinant DNA technology. Granted to Genentech, Inc., this patent broadly covers the production and application of recombinant human epidermal growth factor (EGF). Background and Claims The patent's scope revolves around the isolation, purification, and production of human EGF using recombinant DNA technology. Genentech's primary claims focus on the design of a hybrid gene encoding EGF, where the gene sequence is engineered using bacterial vectors. This engineered gene construct enables the production of recombinant EGF that retains the biological activity of natural EGF. Novelty and Significance The '829 patent's primary contribution lies in its expansion of capabilities in recombinant DNA technology, ushering in a new era of biotechnological innovation. Genentech, a pioneer in recombinant DNA research, demonstrated the feasibility of expressing mammalian proteins in bacteria. This breakthrough not only facilitated large-scale production of EGF but also fostered further research into the application of recombinant DNA technology in basic and applied sciences. Key Embodiments This patent comprises several key embodiments, including: Production of EGF from bacterial expression vectors Isolation and purification of recombinant EGF Characterization of recombinant EGF in terms of immunological and biological properties Technical Aspects From a technical standpoint, the patent involves critical aspects such as the use of bacterial expression vectors to produce biologically active EGF. This approach represents significant technological advancement in the field of recombinant DNA technology, allowing researchers to leverage bacterial systems for large-scale EGF production. Influence on the Field Patent '829 served as a foundational document for the biotechnology sector. Its wide claims and broad applications facilitated the rapid expansion of research and development in the recombinant DNA technology domain. Since its issuance, numerous applications have been filed and granted based on the principles and techniques outlined in this patent. Impact on Future Research Directions The success of Patent '829 spurred further innovations in biotransformation, encouraging research into the expression and production of other recombinant proteins. This has led to advancements in medical treatments and ongoing research in biopharmaceuticals, expanding our understanding of molecular biology. The granting of Patent '829 represents a critical milestone in the biotechnology sector, reflecting the culmination of years of scientific diligence and ingenuity. Genentech's achievement in this domain opened new avenues for research in the field of recombinant DNA technology, significantly contributing to the progression of modern biopharmaceutical research. As biotechnology continues to propel medicine and science forward, the impact of this patent on the trajectory of biopharmaceuticals becomes increasingly apparent.

Drugs Protected by US Patent 4,562,829

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 4,562,829

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	53305
Australia	2464684
Australia	4186285
Australia	570429
Australia	581218
Canada	1233274